NDAORALFOR SUSPENSION
Approved
Dec 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
VIBRAMYCIN (doxycycline) by Pfizer is 12. Approved for rosacea, acne vulgaris, mycoplasma pneumoniae and 9 more indications. First approved in 1967.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIBRAMYCIN (doxycycline) is an oral tetracycline antibiotic approved in 1967 with broad-spectrum activity against bacteria, Mycoplasma, and select parasites. It treats 25+ indications ranging from acne and rosacea to sexually transmitted infections, anthrax, and emerging conditions like COVID-19 and multiple sclerosis. The mechanism of action varies by indication; in rosacea, the mechanism remains unknown, while in infections it inhibits bacterial protein synthesis via ribosomal binding.
$5,000Part D
LOE ApproachingDeclining
Limited commercial momentum; small Part D footprint signals a mature, commoditized product with contracted team structure and focus on cost management rather than growth.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of doxycycline in the treatment of inflammatory lesions of rosacea is unknown. 12.3 Pharmacokinetics Doxycycline capsules are not bioequivalent to other doxycycline products. The pharmacokinetics of doxycycline following oral administration of…
Worked on VIBRAMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.